Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature

ABSTRACT As immunotherapy is becoming more inevitable in everyday oncology, we are witnessing a higher number of patients who are on immunosuppressive medication but are also candidates for immune checkpoint inhibitors (ICIs) treatment. There have been few case reports and several small retrospectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Iva Skocilic, Alojzije Kosic, Ivona Badovinac, Tajana Filipec Kanizaj, Renata Dobrila Dintinjana, Maja Kolak, Anamarija Bukovica, Sanja Ropac, Ivana Mikolasevic
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical Case Reports
Subjects:
Online Access:https://doi.org/10.1002/ccr3.70412
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849709903887728640
author Iva Skocilic
Alojzije Kosic
Ivona Badovinac
Tajana Filipec Kanizaj
Renata Dobrila Dintinjana
Maja Kolak
Anamarija Bukovica
Sanja Ropac
Ivana Mikolasevic
author_facet Iva Skocilic
Alojzije Kosic
Ivona Badovinac
Tajana Filipec Kanizaj
Renata Dobrila Dintinjana
Maja Kolak
Anamarija Bukovica
Sanja Ropac
Ivana Mikolasevic
author_sort Iva Skocilic
collection DOAJ
description ABSTRACT As immunotherapy is becoming more inevitable in everyday oncology, we are witnessing a higher number of patients who are on immunosuppressive medication but are also candidates for immune checkpoint inhibitors (ICIs) treatment. There have been few case reports and several small retrospective studies investigating the use of ICIs in liver transplant recipients mainly with hepatocellular carcinoma and skin cancer, but there is no report regarding the use of atezolizumab for the treatment of metastatic breast cancer in liver transplant recipients. We are presenting a metastatic breast cancer female patient undergoing both immunosuppressive treatment after liver transplantation due to cryptogenic liver failure and anti‐programmed death ligand 1 (PDL1) medication—atezolizumab whose liver enzymes and tacrolimus level we have monitored intensively through 18 months and is still ongoing. Our patient has not presented with any signs of acute graft rejection and has a regression on follow‐up imaging despite the treatment combination.
format Article
id doaj-art-e44e2cb4939f4cf9b50ef680f2fd9e40
institution DOAJ
issn 2050-0904
language English
publishDate 2025-04-01
publisher Wiley
record_format Article
series Clinical Case Reports
spelling doaj-art-e44e2cb4939f4cf9b50ef680f2fd9e402025-08-20T03:15:05ZengWileyClinical Case Reports2050-09042025-04-01134n/an/a10.1002/ccr3.70412Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the LiteratureIva Skocilic0Alojzije Kosic1Ivona Badovinac2Tajana Filipec Kanizaj3Renata Dobrila Dintinjana4Maja Kolak5Anamarija Bukovica6Sanja Ropac7Ivana Mikolasevic8Clinical Hospital Center Rijeka Rijeka CroatiaClinical Hospital Center Rijeka Rijeka CroatiaClinical Hospital Center Rijeka Rijeka CroatiaMerkur Clinical Hospital Zagreb CroatiaClinical Hospital Center Rijeka Rijeka CroatiaClinical Hospital Center Rijeka Rijeka CroatiaClinical Hospital Center Rijeka Rijeka CroatiaClinical Hospital Center Rijeka Rijeka CroatiaClinical Hospital Center Rijeka Rijeka CroatiaABSTRACT As immunotherapy is becoming more inevitable in everyday oncology, we are witnessing a higher number of patients who are on immunosuppressive medication but are also candidates for immune checkpoint inhibitors (ICIs) treatment. There have been few case reports and several small retrospective studies investigating the use of ICIs in liver transplant recipients mainly with hepatocellular carcinoma and skin cancer, but there is no report regarding the use of atezolizumab for the treatment of metastatic breast cancer in liver transplant recipients. We are presenting a metastatic breast cancer female patient undergoing both immunosuppressive treatment after liver transplantation due to cryptogenic liver failure and anti‐programmed death ligand 1 (PDL1) medication—atezolizumab whose liver enzymes and tacrolimus level we have monitored intensively through 18 months and is still ongoing. Our patient has not presented with any signs of acute graft rejection and has a regression on follow‐up imaging despite the treatment combination.https://doi.org/10.1002/ccr3.70412atezolizumabbreast cancerimmune checkpoint inhibitorsliver transplantationmalignancy
spellingShingle Iva Skocilic
Alojzije Kosic
Ivona Badovinac
Tajana Filipec Kanizaj
Renata Dobrila Dintinjana
Maja Kolak
Anamarija Bukovica
Sanja Ropac
Ivana Mikolasevic
Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
Clinical Case Reports
atezolizumab
breast cancer
immune checkpoint inhibitors
liver transplantation
malignancy
title Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
title_full Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
title_fullStr Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
title_full_unstemmed Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
title_short Immune Checkpoint Inhibitors and Liver Transplantation: Case Report and Review of the Literature
title_sort immune checkpoint inhibitors and liver transplantation case report and review of the literature
topic atezolizumab
breast cancer
immune checkpoint inhibitors
liver transplantation
malignancy
url https://doi.org/10.1002/ccr3.70412
work_keys_str_mv AT ivaskocilic immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT alojzijekosic immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT ivonabadovinac immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT tajanafilipeckanizaj immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT renatadobriladintinjana immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT majakolak immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT anamarijabukovica immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT sanjaropac immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature
AT ivanamikolasevic immunecheckpointinhibitorsandlivertransplantationcasereportandreviewoftheliterature